Arcturus Therapeutics Holdings Inc.
ARCT
$18.51
$1.035.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 122.12M | 143.68M | 152.31M | 160.40M | 163.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.12M | 143.68M | 152.31M | 160.40M | 163.87M |
| Cost of Revenue | 121.14M | 122.19M | 140.87M | 133.71M | 145.65M |
| Gross Profit | 987.00K | 21.50M | 11.45M | 26.69M | 18.22M |
| SG&A Expenses | 47.31M | 49.29M | 52.82M | 52.95M | 53.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 194.70M | 225.76M | 247.98M | 240.95M | 252.99M |
| Operating Income | -72.57M | -82.08M | -95.67M | -80.55M | -89.12M |
| Income Before Tax | -60.38M | -68.57M | -80.94M | -62.38M | -70.59M |
| Income Tax Expenses | -217.00K | -371.00K | -3.00K | 263.00K | 1.37M |
| Earnings from Continuing Operations | -60.16 | -68.20 | -80.94 | -62.64 | -71.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.16M | -68.20M | -80.94M | -62.64M | -71.96M |
| EBIT | -72.57M | -82.08M | -95.67M | -80.55M | -89.12M |
| EBITDA | -69.26M | -78.64M | -92.13M | -77.01M | -85.67M |
| EPS Basic | -2.22 | -2.52 | -3.00 | -2.33 | -2.69 |
| Normalized Basic EPS | -1.40 | -1.59 | -1.88 | -1.45 | -1.65 |
| EPS Diluted | -2.23 | -2.53 | -3.00 | -2.33 | -2.69 |
| Normalized Diluted EPS | -1.40 | -1.59 | -1.88 | -1.45 | -1.65 |
| Average Basic Shares Outstanding | 108.30M | 108.14M | 107.91M | 107.54M | 107.05M |
| Average Diluted Shares Outstanding | 108.30M | 108.14M | 107.91M | 107.54M | 107.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |